i-PRF vs A-PRF vs A-PRF+: Clinical Comparison, Centrifugation Protocols & Indications

Mariana Ruiz

Reading time: ~10 minutes | Target audience: Oral and maxillofacial surgeons, implantologists, facial plastic surgeons, aesthetic injectors
Last updated: Nov 12, 2026

Introduction

Over the past two decades, Platelet-Rich Fibrin (PRF) has evolved from the original Leukocyte- and Platelet-Rich Fibrin (L-PRF) protocol introduced by Choukroun into specialized second- and third-generation modalities. Pioneered by scientific advances from researchers including Dr. Shahram Ghanaati and Dr. Joseph Choukroun, modern protocols leverage the Low-Speed Centrifugation Concept (LSCC) to modulate cellular yield, fibrin clot porosity, and physical state.

Today, clinicians frequently choose between three prominent PRF protocols: Injectable PRF (i-PRF), Advanced PRF (A-PRF), and A-PRF+. Understanding the biological rationale, centrifugation speeds (RCF), and clinical indications of each modality allows practitioners to tailor autologous biologics to specific procedural demands.

1. The Low-Speed Centrifugation Concept (LSCC)

In classical high-speed centrifugation (e.g., L-PRF spun at ~2,700 RPM, ~700 × g for 12 minutes), significant centrifugal force drives heavier cells downward. While red blood cells are cleared effectively, a substantial proportion of leukocytes (monocytes, granulocytes) and heavier platelets are also forced to the bottom of the tube, trapped within the erythrocyte layer where they cannot be harvested.

The Low-Speed Centrifugation Concept establishes that by reducing centrifugal speed and time, buoyant forces prevent excessive sedimentation of immune cells and platelets:

  • Higher Platelet and Leukocyte Retention: Cells remain suspended in the upper plasma and fibrin layers rather than being lost to the erythrocyte pellet.
  • Enhanced Growth Factor Concentration: Independent research demonstrates a statistically significant increase in VEGF, TGF-β1, and PDGF-BB release when blood is spun under LSCC parameters.
  • Looser Fibrin Meshwork: Lower shear stress produces a more open, porous fibrin architecture that facilitates endogenous capillary ingrowth and macrophage migration.

2. Modality Breakdown: Physical Form, Spin Protocols & Indications

2.1 A-PRF (Advanced Platelet-Rich Fibrin)

Developed to improve upon classical L-PRF, A-PRF reduces centrifugation speed to allow a higher concentration of neutrophils and macrophages within the fibrin matrix:

  • Typical Centrifugation Protocol: Approximately 1,500 RPM (~200 × g) for 14 minutes.
  • Physical Form: Resilient, dense, gelatinous solid clot.
  • Handling: The clot is compressed in a surgical PRF box to produce durable, tear-resistant PRF membranes or cut into biological cylinders (plugs).
  • Primary Indications: Periodontal guided tissue regeneration (GTR), post-extraction alveolar socket preservation, covering Schneiderian membranes in maxillary sinus floor elevation, and soft-tissue wound dressing.

2.2 A-PRF+ (Advanced Platelet-Rich Fibrin Plus)

Introduced in 2014, A-PRF+ refines the LSCC model even further by dropping centrifugation speed to approximately 1,200–1,300 RPM (~130 × g) for 8 minutes:

  • Physical Form: Softer, highly vascular solid clot with enhanced biological permeability.
  • Biological Advantage: Exhibits significantly higher leukocyte and monocyte distribution throughout the entire length of the clot, rather than clustering solely near the buffy coat boundary. Growth factor release is sustained over an extended 10–14 day window.
  • Primary Indications: Horizontal and vertical ridge augmentation, complex bone graft coverage, diabetic foot ulcers, and refractory soft-tissue dehiscence.

2.3 i-PRF (Injectable Platelet-Rich Fibrin)

Unlike solid A-PRF and A-PRF+, i-PRF is designed specifically to produce a liquid autologous biological concentrate that remains fluid long enough for needle injection without synthetic anticoagulants:

  • Typical Centrifugation Protocol: Approximately 700 RPM (~60 × g) for 3 to 4 minutes (using specialized hydrophobic PET tubes).
  • Physical Form: Pure liquid containing fibrinogen, thrombin, platelets, and leukocytes.
  • Coagulation Window: Remains liquid for approximately 15–20 minutes post-centrifugation before polymerizing into an autologous fibrin gel.
  • Primary Indications:
    • Facial Aesthetics & Trichology: Intradermal injection for peri-orbital dark circles, fine lines, skin texture improvement, and scalp hair follicle rejuvenation.
    • Oral Surgery ("Sticky Bone"): Mixed chairside with particulate bone allograft or xenograft granules; within 3–5 minutes, polymerization binds the particles into a cohesive, moldable graft mass that resists displacement during flap closure.
    • Intra-Articular Injections: Temporomandibular joint (TMJ) arthrocentesis and targeted tendon injections.

3. Comprehensive Protocol Comparison

Parameter i-PRF (Injectable) A-PRF (Advanced) A-PRF+ (Advanced Plus)
Physical State Liquid (15–20 min window) Dense solid clot Hyper-porous solid clot
Centrifuge RPM / Time ~700 RPM / 3–4 min ~1,500 RPM / 14 min ~1,200–1,300 RPM / 8 min
Relative Centrifugal Force ~60 × g ~200 × g ~130 × g
Tube Formulation Hydrophobic medical PET, zero additives Additive-free medical tube Additive-free medical tube
Fibrin Network Structure Polymerizes in situ / post-injection Dense equilateral mesh Open porous matrix, high vascularity
Clinical Delivery 27G–30G needle, cannula, or graft mix Compressed membrane or plug Membrane, plug, or particulate scaffold

4. Clinical Practicalities: Optimizing Results

  • Strict Timing for i-PRF: Because i-PRF contains no anticoagulant, the 3–4 minute spin must be followed immediately by aspiration using an 18G blunt-fill needle and administration within 10–15 minutes. Delayed handling leads to needle clogging as fibrinogen self-polymerizes into fibrin strands.
  • Radius Calibration for Centrifuges: Because RCF depends on rotor radius (r in cm), RPM values vary between centrifuge models. Ensure your clinic converts rpm to RCF correctly using the formula: RCF = 1.118 × 10⁻⁵ × r × RPM².
  • Use Validated Additive-Free Tubes: Using tubes with hidden clot activators (such as silica coatings found in lab SST tubes) invalidates LSCC kinetics and introduces foreign-body risks. Always verify that tubes are certified Class II medical devices manufactured under ISO 13485.

Summary

The progression from L-PRF to A-PRF, A-PRF+, and i-PRF demonstrates how fine-tuning centrifugal physics (LSCC) empowers clinicians to dictate the physical and biological characteristics of autologous fibrin scaffolds. Choosing between solid membranes (A-PRF/A-PRF+) for surgical shielding and liquid concentrates (i-PRF) for tissue injection or sticky bone fabrication provides clinicians with a versatile regenerative toolkit.

Related reading: PRP tube guide.

For validated additive-free PRF collection tubes engineered for both solid and injectable protocols, explore the VivaPRP PRF Collection or view our Complete PRF Tubes Guide.

Back to blog

Leave a comment